News

Greatbatch Medical, Myopore Sutureless Myocardial Pacing Lead

A new epicardial pacing lead has been cleared by the U.S. Food and Drug Adminitysration (FDA) as an option for the implant of a pacemaker, defibrillator, or cardiac resynchronization therapy (CRT...

HRS, remote monitoring, RM, standard of care, CIEDs

A new expert consensus statement by the Heart Rhythm Society (HRS) recommends remote monitoring (RM) become standard of care for patients with cardiovascular implantable electronic devices (CIEDs...

Biotronik, CLS, Itrevia, CRT-D, heart failure

Biotronik announced that a unique physiologic sensor is now available in the latest family of cardiac resynchronization therapy defibrillator (CRT-D) devices. Closed Loop Stimulation (CLS) is the...

Cardiac Resynchonization Therapy (CRT), Implantable cardioverster defibrillators

Medtronic announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm.

Medtronic AdaptResponse Global Clinical Trial Cardiac Resynchronization Therapy

Medtronic Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes — including patient mortality and hospitalizations — in ...

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months, according...

August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with...

Biotronik announced the first implantations worldwide of its new ICD and CRT-D series (implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators).

Medtronic Viva Quad XT CRT-D Adaptiv CRT

August 11, 2014 — Medtronic announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S...

May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when compared to the non-quadripolar group. This...

Medtronic announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -...

ICD, MADIT-CRT trial, long-term followup, ACC.14

Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with a traditional implantable...

Boston Scientific Ingevity Leads MRI Systems Pacemakers CRT EP Lab

Boston Scientific Corp. received CE marking and launched in Europe the Ingevity family of magnetic resonance imaging...

Boston scientific autogen x4 crt-d crt ICD heart failure cardiac

Boston Scientific Corp. has received CE mark approval of its X4 line of quadripolar ...

EP lab crt icd boston scientific europace

An independent study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, showed significant differences in battery longevity...

cardioverter defibrillator cardiac resynchronization therapy biotronik ilesto DX

The U.S. Food and Drug Administration (FDA) approved Biotronik’s Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices)....

Medtronic Inc. announced clinical trial results showing that heart failure patients treated with its AdaptivCRT feature experienced a nearly 50 percent reduction in atrial fibrillation (...

CardioMEMs

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will review two new technologies to help treat heart failure (HF) Oct. 8-9,...

Researchers announced this week that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and an international clinical trial ended...